Anhui Fengyuan Pharmaceutical (000153.SZ) subsidiary receives approval notification for listing application of Fu Manzhu Funnola biochemical raw materials.
Fengyuan Pharmaceutical (000153.SZ) announced that its wholly-owned subsidiary, Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd., has received the approval notice for the market application of potassium competitive acid blocker vonoprazan fumarate issued by the National Medical Products Administration. Vonoprazan fumarate is a P-CAB (Potassium-Competitive Acid Blocker) that can inhibit the production of stomach acid and prevent upper gastrointestinal mucosal damage, mainly used in the treatment of reflux esophagitis and Helicobacter pylori infection.
Anhui Fengyuan Pharmaceutical (000153.SZ) announced that its wholly-owned subsidiary, Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd., has received the approval from the National Medical Products Administration for the issuance of the approval notice for fumaric acid Levonula "Chemical Raw Material Drug Marketing Application". Fumaric acid Levonula is a potassium ion competitive acid blocker (P-CAB) that can inhibit the production of stomach acid and inhibit mucosal injury in the upper gastrointestinal tract. It is mainly used for the treatment of reflux esophagitis and Helicobacter pylori infection.
The acquisition of the approval notice for fumaric acid Levonula "Chemical Raw Material Drug Marketing Application" will enrich the company's product line, optimize the company's product structure, and enhance the company's market competitiveness, which will positively impact the company's future development.
Related Articles
POWERLONG (01238): The plan has obtained approval from the majority of the required plan creditors.
Dingdang Health (Stock code: 09886) announced on May 12th that it has spent HK$12,300 to repurchase 13,000 shares.
Yangzhou Seashine New Materials (300885.SZ) shareholders intend to transfer 3% of the company's shares through inquiry.
POWERLONG (01238): The plan has obtained approval from the majority of the required plan creditors.
Dingdang Health (Stock code: 09886) announced on May 12th that it has spent HK$12,300 to repurchase 13,000 shares.
Yangzhou Seashine New Materials (300885.SZ) shareholders intend to transfer 3% of the company's shares through inquiry.
RECOMMEND
Two Mainland Accounting Firms Approved for H‑Share Audits, Lowering Listing Costs and Deepening Mainland–Hong Kong Market Integration**The Ministry of Finance, the CSRC, and Hong Kong’s Accounting and Financial Reporting Council have approved two additional mainland accounting firms—RSM China and ShineWing—to conduct H‑share audit work, marking the first expansion of the list since 2010.
11/05/2026
HKEX Tightens Rules on Auditor Dismissals as Sudden “Audit Firm Switches” Raise Governance Concerns
11/05/2026
The Chip Stock Frenzy Is Still Accelerating
11/05/2026
